QuorumCivic. Hidden in plain sight Get the app
Bill intelligence

Bill limits drug makers' patent tricks to delay generic competition

S. 2620 — REMEDY Act · Filed by Richard Durbin (D-IL) · 1 cosponsor · Introduced Jul 31, 2025 · Referred to committee

35%
Transparency
Typical bill: 85%
15/100
Hidden-provision risk
Typical bill: 15/100
Generic Drug Access Acceleration

Your members of Congress

Enter a ZIP to see where your representative and both senators stood on this bill.

Looked up on this device — your ZIP is never stored on our servers.

What it does

This bill amends the drug approval process to restrict pharmaceutical companies from using multiple patents to extend market exclusivity. Currently, when a brand-name drug maker files patent information, generic competitors must wait 30 months before launching if the brand-name company sues for patent infringement. The REMEDY Act limits this to ONE patent per drug—the 'covered patent'—that can trigger the 30-month delay, and that choice cannot be changed. This prevents companies from strategically swapping patents to repeatedly extend exclusivity periods and delay generic competition.

Why we flagged it

The bill's operative mechanism is a direct restraint on brand-name pharmaceutical companies' ability to use patent strategy to delay generic competition. It is a pro-competition, pro-consumer measure targeting a specific industry practice.

What the text implies

  • The 'covered patent' selection is permanent and irrevocable—brand-name companies cannot adapt their patent strategy if litigation circumstances change, potentially creating unintended litigation incentives.
  • The bill applies only to drugs approved on or after enactment, leaving existing drugs subject to the old multi-patent evergreening rules; this creates a two-tier system and may incentivize accelerated approvals before enactment.
  • The restriction may increase litigation over which patent qualifies as the 'covered patent,' as brand-name companies will strategically select the patent most likely to survive infringement challenges.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary consumers benefit from faster generic drug entry and lower prices. The bill directly targets 'evergreening'—a practice where brand-name manufacturers strategically use multiple patents to delay generic competition indefinitely. By capping the exclusivity-triggering patent to one per drug, the bill reduces artificial market delays and enables price competition.

Who stands to gain

  • generic pharmaceutical manufacturers
  • pharmacy benefit managers
  • health insurers
  • consumers (via lower drug prices)

Named in the bill

FDA, Federal Food, Drug, and Cosmetic Act, Section 505, brand-name pharmaceutical companies, generic drug manufacturers, patent holders

Where it stands

1 cosponsor: 1 Republicans.

  • Jul 31, 2025 — Introduced · Congress.gov: “Introduced in Senate”
  • Jul 31, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S5000)”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

6 lobbying clients named this bill on 17 disclosure filings across 5 quarters, Sep 2025 to Sep 2026. Those filings disclosed $65,358,162 in lobbying spend. A filing names 54 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 79% of bills with at least one filing.

Richard Durbin, the sponsor, reported $-29,800 in PAC receipts in the 2026 cycle.

  • Pharmaceutical Research and Manufacturers of America — $44,050,000 on 5 filings
  • AARP — $7,640,000 on 2 filings
  • Gsk (fka Glaxosmithkline Inc.) — $6,570,000 on 5 filings
  • Kaiser Foundation Health Plan Inc — $4,020,000 on 3 filings
  • Pharmaceutical Care Management Association — $2,948,162 on 1 filing

Lobbying Disclosure Act filings through Oct 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.

How this was measured

Analysis — Quorum's AI read the bill text published by Congress.gov (4,525 characters) on Nov 7, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 17,910 analysed bills.

Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.

Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Sep 2025 to Sep 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.

As of — lobbying records through Oct 20, 2026 · page rendered 2026-11-22.

“Bill limits drug makers' patent tricks to delay generic competition” QuorumCivic. https://share.quorumcivic.app/bill/119/s2620 Report an error

Correlative observation from public records — not evidence of coordination or wrongdoing, and not financial advice.
This page is the record as of today. The app tells you when it changes.
Quorum analysis of the full bill text · 119th Congress · public record

The week in bills

One email, Sunday: what Congress passed, what it changed, and who paid.

One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.